Newsroom

CHATSWORTH, Calif. & GRENOBLE, France--(BUSINESS WIRE)--Aitech and Teledyne e2v Semiconductors are proud to highlight their continued collaboration in advancing space-grade computing. Through their ongoing partnership, Teledyne e2v’s high-reliability semiconductors are being integrated into Aitech’s SP1, a radiation-tolerant 3U SpaceVPX single-board computer (SBC). Designed for deployment in LEO, GEO, lunar, and deep space missions, the SP1 is a robust computing platform tailored for spacecraft...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 17 February 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 17 February 2026 Number of Public Shares Purchased:...

PARIS--(BUSINESS WIRE)--Regulatory News: WE.CONNECT (Paris:ALWEC): Chiffre d’affaires Données non auditées consolidées En M€ 2025* 2024 Variation** 1er semestre 174,9 120,3 45,4% 2nd semestre 276,3 179,9 53,6% TOTAL 451,2 300,2 50,3% * incluant l’acquisition de EXERTIS FRANCE et de EXERTIS IBERIA en août 2025 **Les variations ont été calculées sur la base des données chiffrées en euros sans arrondi, dans ce tableau et dans le texte. WE.CONNECT (code ISIN FR0013079092 – ALWEC), spécialiste des a...

PARIS--(BUSINESS WIRE)--Regulatory News: Dans le cadre des autorisations consenties par l’Assemblée générale du 23 mai 2025 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d'actions, TotalEnergies SE (LEI : 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) déclare ci-après les achats d’actions propres (FR0000120271) réalisés du 12 février au 13 février 2026 : Jour de la transaction Volume total journalier (en nombre de titres) Prix pondéré moyen journal...

PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (LEI: 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) declares the following purchases of its own shares (FR0000120271) from February 12 to February 13, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares...

PARIS--(BUSINESS WIRE)--  In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (LEI: 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) declares the following purchases of its own shares (FR0000120271) from February 12 to February 13, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Am...

DUBLIN--(BUSINESS WIRE)--IPUT Real Estate ('IPUT'), Dublin's leading property investment company, announces it has raised €175 million in new equity from CBRE Investment Management Indirect Strategies (“CBRE IM”) to continue to grow its prime Dublin office portfolio. IPUT’s office portfolio comprises 30 assets of over 2 million sq. ft., all of which is located in Dublin’s City Centre. IPUT has a ready-to-go development pipeline with the capacity to accommodate over €500 million of investment, a...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones. The company named...

PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce aujourd’hui le renforcement stratégique de son département des Affaires Réglementaires et de la Qualité avec deux nomination...

RAS AL KHAIMAH, United Arab Emirates--(BUSINESS WIRE)--BEYOND Developments Unveils EVERMORE Masterplan on Marjan Beach in Ras Al Khaimah...